About: Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
Creator	Christopher, ; Malhotra, Rajeev Nicholson, J Rotter, Jerome Guo, Xiuqing Haakon, ; Jiang, Wanlin Li, Rebecca Sigurslid, H Tian, Wenjie Wooster, ; Yao, Jie
source	Medline; PMC
abstract	Mortality rates of coronavirus disease 2019 (COVID‐19) continue to rise across the world. Information regarding the predictors of mortality in COVID‐19 patients remains scarce. Herein, we performed a systematic review of published articles, from January 1 to April 24, 2020, to evaluate the risk factors associated with mortality in COVID‐19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (OR 2.5; 95% CI 2.1‐3.1; P<0.00001), coronary heart disease (OR 3.8; 95% CI 2.1‐6.9; P<0.00001) and diabetes (OR 2.0; 95% CI 1.7‐2.3; P<0.00001) were associated with significantly higher risk of death amongst COVID‐19 patients. Those who died, compared to those who survived, differed on multiple biomarker levels on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI 19.0‐69.4; P=0.0006); C‐reactive protein (+66.3 µg/mL, 95% CI 46.7‐85.9; P<0.00001); interleukin‐6 (+4.6 ng/mL, 95% CI 3.6‐5.6; P<0.00001); D‐dimer (+4.6 µg/mL, 95% CI 2.8‐6.4; P<0.00001); creatinine (+15.3 µmol/L, 95% CI 6.2‐24.3; P=0.001) and alanine transaminase (+5.7 U/L, 95% CI 2.6‐8.8; P=0.0003); as well as decreased levels of albumin (‐3.7 g/L, 95% CI ‐5.3 to ‐2.1; P<0.00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end‐organ damage are at higher risk of mortality due to COVID‐19 infection and should be managed with greater intensity. This article is protected by copyright. All rights reserved.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1002/jmv.26050
bibo:pmid	32441789
has license	no-cc
sha1sum (hex)	6ac16f5e19eb94b81518fa94f70e3269e77d5724
schema:url	https://doi.org/10.1002/jmv.26050
resource representing a document's title	Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
has PubMed Central identifier	PMC7280666
has PubMed identifier	32441789
schema:publication	J Med Virol
resource representing a document's body	covid:6ac16f5e19eb94b81518fa94f70e3269e77d5724#body_text
is schema:about of	named entity 'Running' named entity 'COVID-19' covid:arg/6ac16f5e19eb94b81518fa94f70e3269e77d5724 named entity 'Mortality rates' named entity 'mortality' named entity 'mortality' named entity 'COVID-19' named entity 'systematic review' named entity 'CRP' named entity 'PubMed' named entity 'COVID-19 pandemic' named entity 'World Health Organization' named entity 'higher risk' named entity 'cross-sectional' named entity 'case report' named entity 'COVID' named entity 'meta-analysis' named entity 'fatigue' named entity 'variance' named entity 'risk stratification' named entity 'endothelial dysfunction' named entity 'hypertension' named entity 'cell survival' named entity 'COVID' named entity '95% CI' named entity 'sample size' named entity 'heterogeneity' named entity 'hypertension' named entity '1.1' named entity 'COVID' named entity 'fever' named entity 'D-dimer' named entity 'heterogeneity' named entity 'chronic renal disease' named entity 'infection' named entity 'myocardial injury' named entity 'systematic review' named entity 'COVID' named entity 'China' named entity 'comorbidities' named entity 'COVID' named entity 'New York' named entity 'New York' named entity 'COVID' named entity 'cardiometabolic' named entity 'SARS-COV-2' named entity 'PhD' named entity 'meta-analysis' named entity 'coronary heart disease' named entity '95% CI' named entity 'fever' named entity 'COVID' named entity 'BUN' named entity 'creatinine' named entity 'systematic review' named entity 'mortality rate' named entity 'CD8 +' named entity 'comorbidities' named entity 'cardiovascular disease' named entity 'ischemia' named entity 'coagulopathy' named entity '95% CI' named entity 'IL-6' named entity 'diabetes' named entity 'COVID' named entity 'COVID' named entity 'hematologic' named entity 'coronary heart disease' named entity 'confidence intervals' named entity 'diabetes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software